Latest "Gene Ontology Consortium" News Stories

21:06 EDT 23rd October 2018 | BioPortfolio

Here are the most relevant search results for "Gene Ontology Consortium" found in our extensive news archives from over 250 global news sources.

More Information about Gene Ontology Consortium on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Gene Ontology Consortium for you to read. Along with our medical data and news we also list Gene Ontology Consortium Clinical Trials, which are updated daily. BioPortfolio also has a large database of Gene Ontology Consortium Companies for you to search.

Showing "Gene Ontology Consortium" News Articles 1–25 of 4,900+

Tuesday 23rd October 2018

Global and Asia Detergent Viral Inactivation Product Market Status and Future Forecast 20132023 [Report Updated: 20082018] Prices from USD $3000

SummaryKey Content of Chapters Including and can be customizedPart 1:Market Overview, Development, and Segment by Type, Application RegionPart 2:Global Market by company, Type, Application RegionPart 3:Asia Market by company, Type, Application RegionPart 410:Key Regions of Asia Market by Type, ApplicationPart 11:Company information, Sales, Cost, Margin etc.Part 12:ConclusionMarket Segment as fo...

Bioinformatics Tool Review: Genome Variant Analysis Tools

Bioinformatics Tool Review: Genome Variant Analysis Tools   Curator: Stephen J. Williams, Ph.D. The following post will be an ongoing curation of reviews of gene variant bioinformatic software.   The Ensembl Variant Effect Predictor. McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thormann A, Flicek P, Cunningham F. Genome Biol. 2016 Jun 6;17(1):122. […]

When moving out of pilot stage, AAV capsid deamidation may compromise large-scale vector manufacture of gene therapies

When moving out of pilot stage, AAV capsid deamidation may compromise large-scale vector manufacture of gene therapies  #NBTHighlight

Football Players' Concussions Linked to Dyslexia Gene

NewsA gene associated with dyslexia may make some athletes less susceptible to concussions.Contributed Author: 

Plasticell Ltd Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 16102018] Prices from USD $250

SummaryPlasticell Ltd Plasticell is a biotechnology company that develops therapies derived from research using its combinatorial cell culture technology. The company offers therapeutic programs such as expansion of hematopoietic stem cells from bone marrow and cord blood, platelets and immune cells from induced pluripotent stem cells iPSCs and manufacturing of red blood cells. Its CombiCult techn...

Gene Therapy Shows Early Signs of Parkinson's Improvement

This MRI-guided approach transfers the gene therapy directly to specific regions of the brain where conversion to dopamine is impaired. Medscape Medical News

Draft of opium poppy genome provides insight into evolution of gene cluster important for synthesis of opiates  #NBTHighlight

Draft of opium poppy genome provides insight into evolution of gene cluster important for synthesis of opiates  #NBTHighlight

IEEE Blockchain for Clinical Trials EU Forum Brings Focus on Empowering Patients

Six European and international consortia, working groups and patient advocacies to share developments and perspectives on private and public blockchain pilots IEEE, the world's largest technical professional organization dedicated to advancing technology for humanity, and the IEEE Standards Association (IEEE-SA), today announced details of the u...

More Good News For Bayer's Larotrectinib Ahead Of FDA Verdict

An update on Bayer and Loxo's tissue-agnostic therapy for cancers with NTRK gene fusions has impressed, confirming the sustained durable...   

We wrote about desperate parents who found that a few million can buy experimental gene therapy for their children. …

We wrote about desperate parents who found that a few million can buy experimental gene therapy for their children. …

De novo gene mutations in normal human memory B cells

Gene therapy sheep study proves promising enough for human trials

A gene therapy trial originally tested in sheep, to treat a condition known as âday blindnessâ, has been approved for in-human trials.

CyberMDX Joins Medical Device Information, Safety and Security Consortium and Helps Drive Medical Device Security Testing Lab WHISTL

As a founding member of MDISS, CyberMDX will collaborate in national cyber information-sharing and research community to advance patient safety and enhance the security of medical devices CyberMDX, a leading provider of medical cyber security, delivering zero touch visibility and threat prevention for medical devices and clinical assets, announc...

BTIG to Host Fall Biotechnology Conference in New York

BTIG, LLC announced today that it will host the “BTIG Fall Biotechnology Conference” with featured panelists from emerging private and established multinational biotechnology companies. The format of the conference includes one-on-one meetings and panel discussions led by key opinion leaders and BTIG Biotechnology Analysts Tim Chiang, Robert Haz...

Deep multi-region whole-genome sequencing reveals heterogeneity and gene-by-environment interactions in treatment-naive, metastatic lung cancer

Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines

Asuragen to Present at 2018 Association for Molecular Pathology (AMP) Annual Meeting

Corporate workshop, platform presentation, and scientific posters to highlight upcoming genetic kit launches and recent oncology portfolio additions Asuragen, Inc., a molecular diagnostics company delivering easy-to-use products for complex testing in genetics and oncology, will host a corporate workshop, deliver an oral presentation during the poster ...

Ablexis Announces Licensing Agreement with Voyager Therapeutics

Ablexis grants rights to Voyager to use the AlivaMab Mouse platform for research, development and potential commercialization of antibodies Ablexis, LLC, a biopharmaceutical company focused on licensing its AlivaMab Mouse technology for antibody drug discovery, today announced a license

Stoke Therapeutics Announces $90 Million Series B Financing to Advance Novel Oligonucleotide Medicines

Lead candidate to treat the genetic cause of Dravet Syndrome expected to reach clinic by 2020 Stoke Therapeutics today announced that it has completed a $90 million Series B financing to advance its pipeline of antisense oligonucleotide medicines for Dravet Syndrome and other severe genetic diseases. The financing round was led by RTW I...

Two sick children and a $1.5 million bill: One family’s race for a gene therapy cure

One day, gene therapy may help with the rarest of diseases. Some parents aren’t waiting.

Profiles in precision medicine

Advances in DNA testing and gene editing have given people choices that would have been impossible a few decades ago. Here, in their own words, are the stories of four people confronted with these dilemmas.

Dual-vector prodrug activator gene therapy using retroviral replicating vectors

Monday 22nd October 2018

New discovery may lead to better treatment options for pancreatic cancer patients

Pancreatic cancer is one of the most difficult cancers to treat and is a leading cause of cancer-related deaths. Now, Sidney Kimmel Cancer Center - Jefferson Health and Lankenau Institute for Medical Research scientists find that a gene involved in the immune system called IDO2 plays a significant role in pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer.

How gentle touch can turn painful after injury

Researchers identified a gene that’s needed for gentle touch to turn painful after an injury. The study uncovers a possible target for treatments to relieve pain caused by skin injuries.

Pompe Disease Pipeline Review, H2 2018 [Report Updated: 16102018] Prices from USD $2000

Pompe Disease Pipeline Review, H2 2018SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pompe Disease Pipeline Review, H2 2018, provides an overview of the Pompe Disease Metabolic Disorders pipeline landscape.Pompe disease is an inherited disorder caused by defect in a gene called GAA. The GAA gene is responsible for the production of the GAA enzyme acid ...

Quick Search


News Quicklinks